Kiniksa Pharmaceuticals International (KNSA) Gains from Sales and Divestitures (2018 - 2026)

Kiniksa Pharmaceuticals International has reported Gains from Sales and Divestitures for 8 years, with the latest figure at $21474.0 in Q1 2026.

• For the quarter ending Q1 2026, Gains from Sales and Divestitures fell 60.49% year-over-year to $21474.0; the trailing twelve-month figure through Mar 2026 stood at $21474.0 (down 60.49% YoY), and the FY2025 full-year result was $771693.0, changed N/A from the prior year.
• Gains from Sales and Divestitures for Q1 2026 stood at $21474.0, down from $771693.0 in the prior quarter.
• The five-year high for Gains from Sales and Divestitures was $771693.0 in Q4 2025, with the low at $21474.0 in Q1 2026.
• Historically, Gains from Sales and Divestitures has averaged $300577.7 across 5 years, with a median of $250805.0 in 2022.
• Annual changes were most pronounced in 2023 — Gains from Sales and Divestitures surged 103.31% — and 2026, when it sank 60.49%.
• Kiniksa Pharmaceuticals International's Gains from Sales and Divestitures stood at $250805.0 in 2022, then jumped by 85.76% to $465891.0 in 2023, then increased by 29.59% to $603762.0 in 2024, then climbed by 27.81% to $771693.0 in 2025, then sank by 97.22% to $21474.0 in 2026.
• The last three Gains from Sales and Divestitures figures came in at $21474.0 (Q1 2026), $771693.0 (Q4 2025), and $698136.0 (Q3 2025), per Business Quant data.